SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
PGEN

Precigen, Inc. (NASDAQ:PGEN)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$4.21+$0.05 (+1.20%)
 
Market cap
$1.51B
Insider Score
Health Score
Analyst consensus
Listed since
Aug 8, 2013
Market Cap$1.51B+10.2%
Revenue (ttm)$156.94M+2387.6%
Net Income$24.41M+109.9%
EPS$0.04+102.7%
Shares Out358.55M
PE Ratio61.64
Forward PE6.74
Dividendn/a
Ex-Dividend Daten/a
Volume6,067,718
Open$4.16
Previous Close$4.16
Day's Range$4.07 - $4.36
52-Week Range$3.04 - $8.98
Beta0.98
AnalystsBuy
Price Target$15.00(+256.29%)
Earnings DateMar 24, 2027

About PGEN

Precigen, Inc. is an American company dedicated to the discovery and development of cutting-edge gene and cellular therapies. The company also offers disease-modifying treatments, genetically engineered swine for regenerative medicine, and advanced reproductive and embryo transfer technologies. Its extensive portfolio of proprietary platforms includes UltraVector, which leverages advanced DNA construction and computational modeling to engineer complex gene expression programs; mbIL15, a gene designed to enhance immune cell function; the non-viral Sleeping Beauty transposon/transposase system for genetic modification; and AttSite recombinases, tools for precise DNA recombination. Furthermore, Precigen utilizes its AdenoVerse platform, a library of engineered adenovectors for gene delivery and immunotherapy applications, alongside L. lactis, a food-grade bacterium. The company also provides RheoSwitch, an inducible gene switch system offering quantitative, dose-proportionate control over target protein expression's timing and amount; kill switches, designed to selectively eliminate cell therapies within the body; tissue-specific promoters for targeted gene expression; the UltraCAR-T platform for cancer treatment; and the ActoBiotics platform, which employs genetically modified bacteria to deliver proteins and peptides directly to mucosal sites. Precigen maintains strategic collaboration and license agreements with Alaunos Therapeutics, Inc., Ares Trading S.A., Oragenics, Inc., Castle Creek Biosciences, Inc., and Intrexon Energy Partners I and II, LLC. Established in 1998, Precigen, Inc., previously known as Intrexon Corporation, adopted its current name in January 2020 and is headquartered in Germantown, Maryland.

Address
20374 Seneca Meadows Parkway, Germantown, MD, 20876, US
Market Cap
1.51 billion
Employees
160
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$4.51M
Bought
$24.66K

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
1 Buy0 Hold0 Sell

1 firm rating PGEN in the last 3 months, one vote each. Issuer-paid research is not counted.

Financial Health Score
Fair
From PGEN’s reported statements · Q3 2026 (trailing 12 months)

Next catalysts

1 Day
+1.20%
5 Days
-5.18%
1 Month
-34.12%
6 Months
-0.71%
1 Year
+10.21%

$PGEN stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in PGEN holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by PGEN's directors and management

Net Shares Purchased by Insiders−700k−350k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

PGEN Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New PGEN patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to PGEN from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in PGEN

VTIVanguard Morningstar Total Stock Market ETF$31.91M
XBIState Street SPDR S&P Biotech ETF$24.19M
IWMiShares Russell 2000 ETF$21.78M
VXFVanguard Extended Market ETF$15.02M
VTWOVanguard Russell 2000 ETF$7.88M
IWOiShares Russell 2000 Growth ETF$7.53M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from PGEN’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
85
News & Sentiment
20% of score
72

News check: Strong Q3 earnings with 37% revenue growth and early positive cash flow achievement outweigh new buy rating; concrete business momentum dominates.

Recent Insider Activity

Buys
1
Sells
9
Buy Value
$24.66K
Distinct Buyers
1

Insider Score Trend Over Time

+29.0 since Sep 20
0255075100Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 32.5Sep 26 — Insider Score 32.1Sep 27 — Insider Score 32.4Sep 28 — Insider Score 32.4Sep 29 — Insider Score 32.0Sep 30 — Insider Score 32.0Oct 1 — Insider Score 31.2Oct 2 — Insider Score 36.0Oct 3 — Insider Score 30.9Oct 4 — Insider Score 31.1Oct 5 — Insider Score 31.0Oct 6 — Insider Score 30.8Oct 7 — Insider Score 30.6Oct 8 — Insider Score 30.1Oct 9 — Insider Score 30.2Oct 10 — Insider Score 29.3Oct 11 — Insider Score 30.8Oct 12 — Insider Score 31.2Oct 13 — Insider Score 30.8Oct 14 — Insider Score 30.8Oct 15 — Insider Score 30.7Oct 16 — Insider Score 30.6Oct 17 — Insider Score 30.2Oct 18 — Insider Score 30.7Oct 19 — Insider Score 30.4Oct 20 — Insider Score 30.4Oct 21 — Insider Score 30.9Oct 22 — Insider Score 30.3Oct 23 — Insider Score 31.6Oct 24 — Insider Score 31.5Oct 25 — Insider Score 30.9Oct 26 — Insider Score 31.3Oct 27 — Insider Score 31.3Oct 28 — Insider Score 30.8Oct 29 — Insider Score 30.5Oct 30 — Insider Score 29.5Oct 31 — Insider Score 29.2Nov 1 — Insider Score 30.2Nov 2 — Insider Score 31.4Nov 3 — Insider Score 30.8Nov 4 — Insider Score 31.1Nov 5 — Insider Score 31.1Nov 6 — Insider Score 30.8Nov 7 — Insider Score 29.4Nov 8 — Insider Score 30.9Nov 9 — Insider Score 31.6Nov 10 — Insider Score 31.0Nov 11 — Insider Score 30.5Nov 12 — Insider Score 31.0Nov 13 — Insider Score 29.9Nov 14 — Insider Score 28.9Nov 15 — Insider Score 29.9Nov 16 — Insider Score 30.1Nov 17 — Insider Score 29.5Nov 18 — Insider Score 29.0Sep 20Oct 19Nov 18

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

ADDSHedgeye Index Adds ETF1.41%
BBPVirtus Biotech ETF1.36%
GRNJFundstrat Granny Shots US Small- & Mid-Cap ETF1.22%
PCSGPolen 5Perspectives Small-Mid Growth ETF0.56%
QQQSInvesco NASDAQ Future Gen 200 ETF0.39%
FYCFirst Trust Small Cap Growth AlphaDEX Fund0.35%
SFLOVictoryShares Small Cap Free Cash Flow ETF0.30%
XBIState Street SPDR S&P Biotech ETF0.27%
DWASInvesco Dorsey Wright SmallCap Momentum ETF0.24%
IWCiShares Micro-Cap ETF0.22%
OASCOneAscent Enhanced Small and Mid Cap ETF0.17%
FYXFirst Trust Small Cap Core AlphaDEX Fund0.16%

Weight is the stock’s share of each fund’s holdings.